Ivermectin and Long COVID
Few drugs have generated more heat and less light than ivermectin. If you have spent time in COVID or Long COVID communities online, you have probably seen it promoted extensively. If you've used it yourself, please consider adding a review to our database here.
Why Anyone Got Interested
The initial interest was not irrational. Ivermectin is a genuinely important medicine. It is used around the world to treat parasitic diseases such as river blindness and strongyloidiasis. It is inexpensive, off-patent, and generally safe when used at approved doses for approved conditions. Its story is tied to Nobel-winning work on avermectin, the compound family that led to ivermectin.
Early in the pandemic, a laboratory study found that ivermectin could inhibit SARS-CoV-2 replication in cells in a dish. That was a reasonable reason to run clinical trials. But “works in a dish” is not the same as “works in a person.” The concentrations used in those lab experiments were far above what standard human dosing can safely and reliably achieve.
What the COVID Trials Found
The larger, better-controlled trials did not support ivermectin as a COVID treatment.
In the TOGETHER trial in Brazil, ivermectin did not meaningfully reduce hospitalization or prolonged emergency observation, and there was no significant mortality benefit. In the U.S. ACTIV-6 trial, ivermectin was tested at standard and higher/longer dosing; neither version meaningfully improved time to recovery or other major outcomes. COVID-OUT found no significant benefit for its acute COVID primary endpoint. PRINCIPLE, the large U.K. community trial, found a small shortening of recovery time, but no meaningful effect on hospitalization, death, or long-term outcomes, and the investigators did not support routine use.
Systematic reviews that give more weight to higher-quality trials have reached the same general conclusion: no convincing benefit on the outcomes that matter most.
Why Early Studies Looked More Promising
Early enthusiasm rested on small studies, weak designs, and in some cases studies later withdrawn or flagged for serious integrity concerns. When questionable studies were removed and larger randomized trials arrived, the apparent benefit shrank.
There is also an important parasite-related wrinkle. Some early positive signals came from regions where strongyloidiasis is more common. Steroids, used in severe COVID, can trigger dangerous Strongyloides hyperinfection. Ivermectin can prevent or treat that parasite problem. That could create a real benefit in those settings without meaning ivermectin treats SARS-CoV-2 itself.
How to Read the Debate
A recurring pattern in ivermectin advocacy is selective evidence. Some websites pool every positive study, including tiny, uncontrolled, low-quality, or disputed ones, then dismiss large negative trials as flawed or rigged. That is not how evidence assessment works.
The strongest evidence gets the most weight: prospective, randomized, controlled, adequately powered trials with clear outcomes and transparent methods. When those trials repeatedly come back negative, the responsible conclusion changes.
Be especially cautious of anyone selling ivermectin, describing it as a suppressed miracle cure, or claiming that every major independent trial, regulator, and research group across multiple countries is part of the same cover-up.
What About Long COVID?
For established Long COVID, there is no good evidence that ivermectin helps.
There is also one direct prevention signal worth knowing: in COVID-OUT, researchers followed participants for Long COVID after acute treatment with metformin, ivermectin, or fluvoxamine. Metformin reduced Long COVID incidence in that trial; ivermectin did not. The hazard ratio for ivermectin was essentially neutral.
So the case for ivermectin in Long COVID is weak. It depends on extending an acute-COVID rationale that did not hold up well, and the one major trial that looked at Long COVID prevention found no benefit.
Safety
At approved doses for approved parasitic infections, ivermectin is generally safe. That does not mean all ivermectin use is safe.
Higher doses, repeated unsupervised courses, drug interactions, and veterinary formulations carry real risks. Reported toxicity includes nausea, vomiting, diarrhea, low blood pressure, dizziness, confusion, loss of coordination, hallucinations, seizures, coma, and, rarely, death. Veterinary products are not interchangeable with human prescriptions.
The Bottom Line
Ivermectin is a valuable antiparasitic medicine. For COVID-19, multiple large trials do not show meaningful clinical benefit, and evidence reviews do not support routine use. For Long COVID, there is no good evidence that it treats established illness, and COVID-OUT found no prevention benefit.
Nevertheless, if you're looking for a provider that can prescribe it, search our database here.